Table 3.
Additional Treatments for Diabetic Macular Edema from 14-Week to 56-Week Visit
| Sham+ Focal/Grid/PRP Laser N = 123 |
Ranibizumab+ Focal/Grid/PRP Laser N = 113 |
Triamcinolone+ Focal/Grid/PRP Laser N = 109 |
|
|---|---|---|---|
| 14 weeks to 56 weeks | |||
| Eyes with additional treatments (number of treatment applied) | 71 (120) | 48 (84) | 45 (78) |
| Additional treatment, No.* | |||
| Bevacizumab | 14 | 12 | 9 |
| Ranibizumab | 1 | 0 | 3 |
| Triamcinolone | 3 | 8 | 2 |
| Pegaptanib | 0 | 0 | 3 |
| Laser | 31 | 10 | 21 |
| Vitrectomy | 2 | 1 | 0 |
| Bevacizumab + Triamcinolone | 2 | 0 | 2 |
| Ranibizumab+Triamcinolone | 0 | 1 | 0 |
| Bevacizumab + Laser | 8 | 5 | 0 |
| Ranibizumab + Laser | 0 | 3 | 0 |
| Triamcinolone + Laser | 7 | 4 | 5 |
| Pegaptanib+Laser | 1 | 0 | 0 |
| Triamcinolone + Vitrectomy | 0 | 1 | 0 |
| Pegaptanib+Vitrectomy | 0 | 1 | 0 |
| Triamcinolone + Laser+Vitrectomy | 0 | 1 | 0 |
| Bevacizumab + Triamcinolone + Laser | 2 | 1 | 0 |
| Eyes with anti-VEGF Treatment (number of treatments applied) | 28 (39) | 23 (32) | 17 (32) |
*
Number of eyes, each combination of treatment only counted once. VEGF=Vascular endothelial growth factor; PRP=Panretinal photocoagulation.